Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Biologics Market Outlook to 2020
     3.1 Market Size
     3.2 Market Segmentation

4. Global Biosimilars Market Outlook 2020
     4.1 Market Size
     4.2 Market Segmentation by Application
            4.2.1 Erythropoietin (EPO)
            4.2.2 Human Growth Hormone (HGH)
            4.2.3 Granulocyte- Colony Stimulating Factor (G-CSF)
            4.2.4 Monoclonal Antibody (mAb)
            4.2.5 Insulin
            4.2.6 Interferon (IFN)
     4.3 Market Segmentation by Geography
            4.3.1 Europe
            4.3.2 Asia-Pacific
            4.3.3 Others

5. Market Drivers and Challenges
     5.1 Drivers
            5.1.1 Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market
            5.1.2 Shrinking Healthcare Budgets to Carve Way for Biosimilars
            5.1.3 Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
     5.2 Challenges
            5.2.1 Need for the Development of Manufacturing Capabilities
            5.2.2 Greater Litgation Risk
            5.2.3 High Cost of Development Accompanied with Low Adoption
            5.2.4 Interchangeability/ Substitutability

6. Market Trends and Developments
     6.1 Plant based Manufacturing Platforms for Biosimilars
     6.2 Developing Economies Emerge as Potential Markets for Biosimilar Production

7. Mergers and Acquisitions

8. Porter's Analysis

9. Competitive Landscape
     9.1 Market Share of Major Players
     9.2 Profiles
            9.2.1 Biocad
            9.2.2 Celltrion
            9.2.3 Dong-A Pharmaceutical Co., Ltd
            9.2.4 Hospira
            9.2.5 Intas
            9.2.6 Sandoz
            9.2.7 Stada Arzneimittel
            9.2.8 Teva

10. Future Outlook